拓展肝癌肝切除术的边界
本文综述了肝细胞癌(HCC)和肝内胆管癌(iCCA)外科切除的进展。HCC多伴肝硬化而iCCA常无明确危险因素;手术规划需评估未来残肝体积与功能储备以降低术后肝衰竭风险。结合系统与局部治疗可使初始不可切除肿瘤降期转化,分子生物学进展有望进一步扩大可切除范围。
要点
- HCC多伴肝硬化,iCCA常无明确危险因素,两者手术规划均需评估残肝体积与功能。
- 系统与局部治疗联合策略可实现降期和转化,使初始不可切除肝肿瘤获得手术机会。
- 分子生物学与新治疗策略的进展,尤其iCCA,有望进一步拓展可切除边界。
核心结论
- 外科切除是HCC和iCCA根治性治疗的基石,综合治疗与分子进展正不断拓展可切除边界。
研究设计与样本
- 本文为综述,围绕HCC和iCCA肝切除术的规划、肿瘤学原则及综合治疗策略进行论述。
主要发现
- HCC患者多存在 underlying 肝硬化,而iCCA常缺乏可识别的危险因素。
- 手术规划需评估未来残肝体积和功能储备,以降低术后肝衰竭风险。
- 系统与局部治疗整合策略使初始不可切除肝恶性肿瘤得以降期和转化,扩大手术适应人群。
- 分子生物学认识和新治疗策略的进展,尤其在iCCA中,有潜力进一步扩展可切除性边界。
临床怎么用
- 术前应同时评估残肝体积与功能储备,而不仅关注体积,以降低术后肝衰竭风险。
- 对初始不可切除肝肿瘤,可考虑系统与局部治疗联合策略争取降期或转化后手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surgical resection is a cornerstone of curative therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), the two most common primary liver malignancies. In most patients with HCC, underlying cirrhosis is present, whereas in iCCA an identifiable risk factor is often absent. Regardless of tumour type, surgical planning must account for the future liver remnant to minimise the risk of post-hepatectomy liver failure, evaluating not only its volume but also its functional reserve. Furthermore, a deeper knowledge of surgical oncological principles combined with integrative strategies, including systemic and locoregional therapies, has enabled downstaging and conversion of initially unresectable liver malignancies, expanding surgical eligibility across a growing spectrum of hepatic tumoural conditions. Additionally, advances in the understanding of molecular biology and new treatment strategies, particularly in iCCA, have the potential to further extend the boundaries of resectability.
引用
- Sapisochin G, O'Kane GM, Zorigtbaatar A, et al. Pushing the boundaries of liver resection for liver cancer. J Hepatol. 2026. PMID: 42493369. doi:10.1016/j.jhep.2026.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。